Imunon, Inc. cash flow to debt ratio of -1.38K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Imunon, Inc.'s free cash flow has increased -24.93% from $-18.88M last year to $-14.18M, signaling increasing performance

Imunon, Inc.'s debt to equity ratio is 0.19, which means that the company's assets are healthy financed, signaling financial stability.

Imunon, Inc.'s debt has decreased relative to shareholder equity from 0.27 last year to 0.19 today, signaling strengthened financials

Imunon, Inc. has a net cash position, so leverage is healthy.

Imunon, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Imunon, Inc. has insufficient data to evaluate this check.

Imunon, Inc.'s short-term assets of $10.72M exceed its short-term liabilities of $4.62M

Imunon, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Imunon, Inc.'s return on equity of -268.93%, is lower than 15.00%, indicating bad performance

Imunon, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Imunon, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Imunon, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Imunon, Inc. has negative free cash flow, indicating cash burn

Imunon, Inc.'s yearly earnings has increased -22.15% since last year from $-18.62M to $-14.49M, signaling increasing performance

Imunon, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 64.49% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Imunon, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Imunon, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Imunon, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Imunon, Inc. has insufficient data to evaluate this check.

Imunon, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Imunon, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Imunon, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Imunon, Inc. has insufficient data to evaluate this check.

Imunon, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Imunon, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Imunon, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue